Michelle Mierzwa, MD

Dr. Mierzwa has 13 years of clinical experience in treatment of head and neck cancer. Her clinical research interests have included novel chemoradiation regimens for head and neck cancers, as well as imaging markers and biomarkers of tumor response to radiation and toxicity. Specifically, she collaborates with the Departments of Otolaryngology and Medical Oncology to develop clinical trials to identify for oropharynx cancer patients who may be eligible for de-escalation of chemoradiation or may require intensified therapy. She is also the PI of an ongoing novel oropharynx cancer surveillance and survivorship protocol.

Administrative Assistant: Rebecca Roulo, [email protected]

- Advanced imaging techniques and imaging markers of response to radiotherapy in head and neck cancer
- Development of prognostic and predictive biomarkers in head and neck cancer
- Outcome modelling for tumor control and toxicity in head and neck cancer treated with radiotherapy Clinical trial development to de-escalate radiotherapy in oropharynx cancer
- Clinical trial development using imaging markers to improve tumor control in high-risk head and neck cancer treated with radiotherapy
- Head and neck cancer